Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Can Salt-&-Pepper Skin Mean Systemic Sclerosis?

Wesam Gouda, MBBCh, MSc; Abdelhafeez Moshrif, MBBCh, MSc, MD; Fatma H. El Nouby, MBBCh, MSc, MD; & Amal Fehr, MBBCh, MSc, MD  |  Issue: September 2019  |  September 17, 2019

Light micrograph of a vascular lesion (center) caused by systemic sclerosis.

Light micrograph of a vascular lesion (center) caused by systemic sclerosis.
CNRI / Science Source

Systemic sclerosis (SSc) is a multi-system connective tissue disease in which skin and internal organ fibrosis are associated with an obliterative micro-vasculopathy and a degree of inflammation.1 Patients often report it takes one to three years from the appearance of the first signs and symptoms before they receive a diagnosis. The signs and symptoms of systemic sclerosis can be mistaken for any number of diseases, depending on the predominant symptom at the time of examination.3 Early detection provides the opportunity to manage the disease process before damage and fibrosis lead to organ failure and poor outcomes.4

A salt-and-pepper appearance of the skin is just one of many changes observed in the skin of patients with systemic sclerosis.5 It is one of the earliest cutaneous findings in systemic sclerosis.6 Occasionally, it may be the sole cutaneous manifestation.5

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Below, we present a case of systemic sclerosis diagnosed five years from the first presentation, which was pseudo-vitiligo, i.e., salt-and-pepper skin pigmentation.

The Case

Figures 1, 2, 3 & 4

Figures 1, 2, 3 & 4
These photos show salt-and-pepper pigmentation over the patient’s upper back, trunk and upper extremity.

A 30-year-old female patient from Egypt presented to the rheumatology department with chief complaints of pain and swelling of both hands, and thickening and hardening of the skin over her extremities for the past two months. The patient had first become symptomatic in 2013, when her symptoms started as painless skin pigmentation over her neck, back and shoulder, which were diagnosed as vitiligo. At that time, she received systemic psoralen and ultraviolet A therapy for six months with a moderate response.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In April 2015, she had a history of heartburn and regurgitation, which she treated with antacids. In the winter of 2016, she developed Raynaud’s in her fingertips, which usually resolved after she warmed her hands.

Her past medical and family history was otherwise unremarkable. Her physical exam­ination was notable for salt-and-pepper pigmentation over her back, chest and arms (Figures 1–4, below), and skin tightening over her fingers, hand and forearm. Her right wrist and all metacarpo­phalangeal joints were swollen and tender with normal range of motion. There was no associated digital pallor or cyanosis.

A 5 mm punch skin biopsy of the patient’s forearm was sent for histopathological examination, which demonstrated epidermal atrophy and perivascular lymphocytic and plasma cell infiltrates in the superficial and deep dermis (see Figure 5, p. 20). Her routine laboratory tests were unremarkable. Her anti-Scl-70 antibodies, anti-centromere antibodies, antinuclear antibody, thyroid function tests, rheuma­toid factor, chest X-ray, pulmonary function testing, electrocardiogram and echocardiogram were normal. The clinical and histopathologic findings were consistent with a diagnosis of systemic sclerosis in our patient.

We treated the patient with oral prednisone, non-steroidal anti-inflammatory drugs, phosphodiesterase type 5 inhibitor, mycophenolate mofetil, prokinetics and a proton pump inhibitor. The patient symptomatically improved with regard to arthritis and gastrointestinal symptoms. We continue to see her in our outpatient clinic.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:case reportsalt and pepper skinsystemic sclerosis (SSc)

Related Articles

    Capillaroscopy a Safe and Direct Method for SSc Diagnosis

    June 13, 2011

    Seeing vessels clearly can help with discovery and timely treatment

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    Progress Continues in Systemic Sclerosis

    March 1, 2010

    Advances in genetics and potential therapies shed new light on the disease

    More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern

    June 14, 2017

    Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences